These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

146 related items for PubMed ID: 38988600

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Erenumab in highly therapy-refractory migraine patients: First German real-world evidence.
    Scheffler A, Messel O, Wurthmann S, Nsaka M, Kleinschnitz C, Glas M, Naegel S, Holle D.
    J Headache Pain; 2020 Jul 03; 21(1):84. PubMed ID: 32620151
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Migraine-related disability, impact, and health-related quality of life among patients with episodic migraine receiving preventive treatment with erenumab.
    Buse DC, Lipton RB, Hallström Y, Reuter U, Tepper SJ, Zhang F, Sapra S, Picard H, Mikol DD, Lenz RA.
    Cephalalgia; 2018 Sep 03; 38(10):1622-1631. PubMed ID: 30086681
    [Abstract] [Full Text] [Related]

  • 28. Effect of erenumab on the reversion from chronic migraine to episodic migraine in an Asian population: A post hoc analysis of the DRAGON study.
    Wang SJ, Kim BK, Wang H, Zhou J, Wan Q, Yu T, Lian Y, Arkuszewski M, Ecochard L, Snellman J, Wen S, Yin F, Li Z, Su W, Yu S.
    Headache; 2024 May 24. PubMed ID: 38785393
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Effect of switching to erenumab in non-responders to a CGRP ligand antibody treatment in migraine: A real-world cohort study.
    Overeem LH, Lange KS, Fitzek MP, Siebert A, Steinicke M, Triller P, Hong JB, Reuter U, Raffaelli B.
    Front Neurol; 2023 May 24; 14():1154420. PubMed ID: 37034092
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. [Clinical experience with erenumab during the first year of treatment].
    Caso-González A, Leralta-González C, Sanz-Alonso V, Iturbe-Heras M, Hernando-de la Bárcena I, Obaldia-Alaña C.
    Rev Neurol; 2022 Jan 01; 74(1):8-14. PubMed ID: 34927700
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. One-year prospective real-world assessment of effectiveness and safety of erenumab in migraine prevention: results of the French FHU INOVPAIN registry study.
    Lanteri-Minet M, Fabre R, Martin C, Pradat K, Alchaar A, Bozzolo E, Duchene ML, Van Obberghen EK, Donnet A, Fontaine D.
    J Headache Pain; 2023 Nov 08; 24(1):152. PubMed ID: 37940860
    [Abstract] [Full Text] [Related]

  • 35. Matching-adjusted indirect comparisons of oral rimegepant versus placebo, erenumab, and galcanezumab examining monthly migraine days and health-related quality of life in the treatment of migraine.
    Popoff E, Johnston K, Croop R, Thiry A, Harris L, Powell L, Coric V, L'Italien G, Moren J.
    Headache; 2021 Jun 08; 61(6):906-915. PubMed ID: 34021585
    [Abstract] [Full Text] [Related]

  • 36. Initial experience with novel CGRP-receptor inhibitor therapy in Migraine in the United Arab Emirates: a retrospective observational study.
    Dinh BBK, Aziz WH, Terruzzi A, Krieger DW.
    BMC Neurol; 2021 Dec 14; 21(1):486. PubMed ID: 34906111
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial.
    Tepper S, Ashina M, Reuter U, Brandes JL, Doležil D, Silberstein S, Winner P, Leonardi D, Mikol D, Lenz R.
    Lancet Neurol; 2017 Jun 14; 16(6):425-434. PubMed ID: 28460892
    [Abstract] [Full Text] [Related]

  • 39. Pooled retrospective analysis of 70 mg erenumab in episodic and chronic migraine: a two tertiary headache centers experience during clinical practice.
    Storch P, Burow P, Möller B, Kraya T, Heintz S, Politz N, Naegel S.
    Acta Neurol Belg; 2022 Aug 14; 122(4):931-937. PubMed ID: 34406609
    [Abstract] [Full Text] [Related]

  • 40. Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study.
    Barbanti P, Aurilia C, Cevoli S, Egeo G, Fofi L, Messina R, Salerno A, Torelli P, Albanese M, Carnevale A, Bono F, D'Amico D, Filippi M, Altamura C, Vernieri F, EARLY Study Group.
    Headache; 2021 Oct 14; 61(9):1351-1363. PubMed ID: 34309862
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.